PRAC1: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: PRAC1

NCBI ID: G84366

PRAC1

PRAC1: A Potential Drug Target and Biomarker for Prostate Cancer

Prostate cancer is a leading cause of cancer death in men worldwide, with an estimated 17,000 new cases and 9,000 deaths in the United States in 2020. Despite advances in treatment, the survival rate for advanced prostate cancer remains poor, with a five-year survival rate of only 14%. Therefore, there is a need for new treatments and biomarkers to improve outcomes for prostate cancer patients.

PRAC1 is a protein that has been identified as a potential drug target and biomarker for prostate cancer. It is a 22-kDa protein that is expressed in various tissues and cells, including prostate epithelial cells, and has been shown to play a role in cell signaling pathways, including TGF-β signaling, which is involved in cell growth, differentiation, and survival.

In addition to its potential drug target and biomarker properties, PRAC1 has also been shown to be involved in the development of prostate cancer. Studies have shown that PRAC1 expression is significantly associated with the development of prostate cancer, with higher PRAC1 expression levels being associated with greater cancer risk. Furthermore, inhibition of PRAC1 has been shown to enhance the effectiveness of anti-prostate cancer therapies, including androgen deprivation therapy (ADT) and radiation therapy.

Despite the potential benefits of PRAC1 as a drug target and biomarker for prostate cancer, much more research is needed to fully understand its role and to develop effective treatments. One approach to studying PRAC1 is through the use of RNA interference (RNAi) technology, which allows researchers to reduce the amount of PRAC1 protein produced in cells. RNAi screening has identified potential targets for PRAC1, including the androgen receptor (AR), which is involved in prostate cancer development, and the TGF-β pathway, which is involved in cell signaling.

Another approach to studying PRAC1 is through the use of cancer cell-based assays, such as the PCR-based assay or the cell-based assay. These assays allow researchers to assess the effects of drugs on the growth and survival of cancer cells, including those derived from prostate epithelial cells. Recently, PRAC1 has been shown to be a potential drug target and biomarker for prostate cancer in cell-based assays, with inhibition of PRAC1 leading to increased cell growth inhibition and increased sensitivity to androgen deprivation therapy.

In addition to its potential drug target and biomarker properties, PRAC1 has also been shown to be involved in the development of prostate cancer. Studies have shown that PRAC1 expression is significantly associated with the development of prostate cancer, with higher PRAC1 expression levels being associated with greater cancer risk. Furthermore, inhibition of PRAC1 has been shown to enhance the effectiveness of anti-prostate cancer therapies, including androgen deprivation therapy (ADT) and radiation therapy.

In conclusion, PRAC1 is a protein that has been identified as a potential drug target and biomarker for prostate cancer. Its expression is associated with the development of prostate cancer and has been shown to enhance the effectiveness of anti-prostate cancer therapies. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: PRAC1 Small Nuclear Protein

The "PRAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets